Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$84.23 - $157.98
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.77M
Market Cap
$12.17B
Enterprise ValueN/A
Total Cash (Recent Filing)$943.50M
Total Debt (Recent Filing)$447.50M
Price to Earnings (P/E)40.9
Beta0.64
Next Earnings
Aug 05, 2025EPS Estimate
0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding98,965,820
10 Day Avg. Volume1,575,439
30 Day Avg. Volume1,769,126
Financial Highlights & Ratios
PEG Ratio-3.83
Price to Book (P/B)4.78
Price to Sales (P/S)0.00
P/FCF Ratio24.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$161.25Price Target Upside35.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Neurocrine News
Bulls Say, Bears Say
Bulls Say
Product LaunchThe Crenessity launch can drive NBIX shares.
Revenue GrowthNBIX reported record new patient starts for Ingrezza and maintained its 2025 outlook, contributing to a significant positive move in the stock.
Sales PerformanceRecord new patient starts were attributed to the sales force expansion pull-through and improving formulary access.
Bears Say
Market ChallengesIngrezza 2025 commercial dynamics present challenges.
Sales Growth ChallengesTo reach the low end of the Ingrezza guide (~$2.5B), sales going forward would need to grow >8% relative to 2024, which is viewed as particularly challenging.
Ownership Overview
1.09% Insiders
25.67% Mutual Funds
26.26% Other Institutional Investors
18.44% Public Companies and Individual Investors
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $84.23 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $12.17B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Aug 05, 2025 which is in 74 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on May 05, 2025. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.535 by -$0.455.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 0.98.
How many shares outstanding does Neurocrine have?
Neurocrine has 98,965,820 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $0.08 in its last earnings report, missing expectations of $0.535. Following the earnings report the stock price went up 8.355%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
Neurocrine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$161.25 (35.37% Upside)
$161.25 (35.37% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.22%
12-Months-Change
Fundamentals
Return on Equity
12.43%
Trailing 12-Months
Asset Growth
6.20%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
NBIX Company Deck
NBIX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong performance in new patient starts for INGREZZA and a successful launch of CRENESSITY, highlighting significant achievements in R&D and financial strength. However, challenges in reauthorization and the impact of the Inflation Reduction Act were noted, affecting reimbursement dynamics and sales. Despite these challenges, the company remains well-positioned for future growth.Read More>NBIX Stock 12 Month Forecast
Average Price Target
$161.25
▲( 35.37% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Intra-Cellular Therapies
―